Leukemia Therapeutics Treatment Market
Market Insights on Leukemia Therapeutics Treatment covering sales outlook, demand forecast & up-to-date key trends
Leukemia Therapeutics Treatment Market by Treatment Type, Molecule Type, Mode of Administration & Region - Forecast 2022 – 2032
Leukemia Therapeutics Treatment Market Overview (2022-2032)
[250 Pages Report] During the forecast period, the leukemia therapeutics treatment market is expected to record a CAGR of 7.1 per cent to reach a valuation of US$ 17 Bn by 2024, from a valuation of US$ 13 Bn in 2020.
The increased prevalence of acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and chronic myeloid leukemia (CML), as well as growing authorization of novel and inventive medicines and immunotherapies, are driving leukemia therapeutics treatment market expansion.
|
Report Attribute |
Details |
|
Estimated Base Year Value (2021) |
US$ 13.5 Bn |
|
Expected Market Value (2024) |
US$ 17 Bn |
|
Projected Growth Rate (2022-2032) |
7.1% CAGR |
On account of the growing number of people suffering from leukemia, the global leukemia therapeutics treatment market is driven by technological developments and breakthroughs in the field of blood cancer diagnostics.
Moreover, raising public awareness about the benefits of preventive healthcare is likely to move the demand for leukemia therapeutics treatment forward throughout the forecast period. Government initiatives and programs aimed at increasing cancer awareness are expected to drive leukemia therapeutics treatment market expansion until 2026.
Biopsy is the most prevalent technique of diagnosis for this type of cancer, although imaging is predicted to expand in the near future as technology improves and impacts the demand for leukemia therapeutics treatment.
Tyrosine kinase inhibitors dominated the global leukemia therapeutics treatment market due to their superior efficacy and fewer side effects when compared to the rest of the pharmacological class. The majority of treatments and medications are delivered through intravenous, subcutaneous, intramuscular, and intrathecal injections.
Chemotherapy is expected to increase substantially over the next few years. The increased incidence of leukemia cases is the primary factor driving the expansion of the chemotherapy segment and rising the demand for leukemia therapeutics treatment.
In order to maintain their competitive advantage and expand into new regional markets, many companies are focusing on developing breakthrough treatments for the treatment of leukemia. Chemotherapy is, therefore, the most common treatment choice for most people with leukemia. Furthermore, an increase in financing for firms active in leukemia research is likely to improve the leukemia therapeutics treatment market.
Let us know your requirement to get
100% FREE customization
What are the Key Factors Impacting the Leukemia Therapeutics Treatment Market?
Leukemia can be diagnosed by bone marrow tests, platelet count, and WBC (white blood cell) differential count test. Leukemia can be treated by blood transfusion, immunotherapy, bone marrow transplantation, radiation therapy, and chemotherapy.
Commercially available drug in the market driving the demand for leukemia therapeutics treatment includes Gleevec, Bosulif, Sprycel, Iclusig and others. Drugs that are in clinical trials expected to launch in the market within the next few (3 to 5) years include Bosutinib, Omapro, ga101/rg7159, Vidaza, Dacogen, Midostaurin, Vosaroxin, Quizartinib, Graspa, and Marqibo.
The leukemia therapeutics treatment market share consists of chronic leukemia, a type of blood cancer caused by uncontrolled growth of the WBC cells in our body. Chronic leukemia is a type of myeloproliferative disease, which is characterized by chromosomal translocation.
Patients suffering from chronic leukemia show increased susceptibility to bacterial infections, thrombocytopenia, and anemia and may also have enlarged spleen, which causes pain on the left side.
The incidence rate of chronic leukemia is high in men and is the second most common type of cancer occurring in male adults, which further leads to high demand for leukemia therapeutics treatment. Women who are above 50 years of age make up a huge part of leukemia therapeutics treatment market share as they largely suffer from this chronic disease.
Treatment for chronic leukemia depends on the phase of the disease that can be chronic, accelerated, or the blast phase and the treatment for chronic leukemia includes chemotherapy, stem cell transplants, and biologic therapies.
Acute myeloid leukemia therapeutics treatment market share is developing at a speedy pace. In the disease process, immature blood cells are present in the bone marrow. Symptoms found in patients due to the disease are flu, loss of weight, body ache, body pain and spots on skin. Chemotherapy, stem cell transplants and biologic therapies are the major factors included in the demand for leukemia therapeutics treatment.
About 90% of leukemia cases occur in middle age and progresses with aging. Therefore, the leukemia therapeutics market is poised to grow with the rise in the aging population and increasing incidences of leukemia. Drugs such as Gleevec, Sprycel and Iclusig are commercially available for the treatment of leukemia, taking the demand for leukemia therapeutics treatment forward.
What are the Significant Drivers to the Leukemia Therapeutics Treatment Market Growth?
Gleevec was the first leukemia drug introduced in 2001. Since then, there has been a revolutionary change in the quality of life of patients as compared to the former chemotherapy drugs. Globally the elderly people, 60 years and above, are growing, and it is expected that this age group will cross the 2 billion mark in 2050, stated by the United Nations Population Division. Hence the leukemia therapeutics market will also grow significantly.
Adverse events (cytotoxic) associated with nearly all kinds of leukemia therapeutics treatment might restrict the global market demand for leukemia therapeutics treatment.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystHow is the Leukemia Therapeutics Treatment Market Segmented on the Basis of Region?
North America dominates the global leukemia therapeutics treatment market due to the high prevalence rate of leukemia (acute, chronic) and extensive technological advancement (diagnosis) in this region. Europe represents the second largest market demand for leukemia therapeutics treatment due to its large geriatric population base.
In addition, Asia-Pacific and RoW hold the third and fourth position in the global leukemia therapeutics treatment market, respectively, due to less prevalence rate of leukemia and lack of proper healthcare facilities in a few Asian and African countries. The leukemia therapeutics treatment market will grow significantly and the total growth will depend on pipeline products and metabolic inhibitors, a tyrosine kinase receptor FLT -3 of Novartis, and some other capable molecules, improving the demand for leukemia therapeutics treatment.
Who are the Key Players in the Leukemia Therapeutics Treatment Market?
Major market players contributing to the global leukemia therapeutics treatment market share include Ambit Biosciences Corporation, Biogen Idec, Inc., Ariad Pharmaceuticals, Inc., Bristol-Myers Squibb, Novartis Pharmaceuticals, Pfizer and others.
The US Food and Drug Administration approved AbbVie's VENCLEXTA therapy in combination with azacitidine, decitabine, or low-dose cytarabine in October 2020. The treatment is for acute myeloid leukaemia (AML) in people aged 75 and up, as well as those with comorbidities who are unable to receive aggressive chemotherapy.
Bristol Myers Squibb received FDA approval for Onureg for the continuing treatment of adult patients with AML in September 2020. Following intense chemo, patients who have achieved their initial full remission or remission with incomplete blood recovery are eligible for this treatment.
A unified Market Research Subscription Platform, built for today's disparate research needs.
Scope Of Report
|
Report Attribute |
Details |
|
Growth rate |
CAGR of 7.1% from 2022 to 2032 |
|
Base year for estimation |
2021 |
|
Historical data |
2015 – 2020 |
|
Forecast period |
2022 – 2032 |
|
Quantitative units |
Revenue in USD billion, volume in kilotons, and CAGR from 2022 to 2032 |
|
Report coverage |
Revenue forecast, volume forecast, company ranking, competitive landscape, growth factors, and trends, Pricing Analysis, |
|
Segments covered |
Treatment Type, Molecule Type, Type, Mode of Administration, Region |
|
Regional scope |
North America; Western Europe, Eastern Europe, Middle East, Africa, ASEAN, South Asia, Rest of Asia, Australia and New Zealand |
|
Country scope |
U.S.; Canada; Mexico; Germany; U.K.; France; Italy; Spain; Russia; Belgium; Poland; Czech Republic; China; India; Japan; Australia; Brazil; Argentina; Colombia; Saudi Arabia; UAE; Iran; South Africa |
|
Key companies profiled |
Ambit Biosciences Corporation, Biogen Idec, Inc., Ariad Pharmaceuticals, Inc., Bristol-Myers Squibb, Novartis Pharmaceuticals, Pfizer and others. |
|
Customization scope |
Free report customization (equivalent to up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
|
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. |
Key Segments
By Treatment Type:
- Targeted Drugs
- Chemotherapy
By Molecule Type:
- Biologics
- Small Molecules
By Mode of Administration:
- Injectable
- Oral
By Type:
- AML
- CML
- ALL
- CLL
By Region:
- North America
- Latin America
- Asia Pacific
- Europe
- MEA
Frequently Asked Questions
The leukemia therapeutics treatment market is estimated to record a 7.1% CAGR during the forecast period.
North America accounts for the largest revenue share in leukemia therapeutics treatment market.
Product launches, mergers, and collaborations are being used by industry players to increase their leukemia therapeutics treatment market share.
Table of Content
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. Value Chain Analysis
3.5.1. Profit Margin Analysis
3.5.2. Service Providers
3.6. PESTLE and Porter’s Analysis
3.7. Regulatory Landscape
3.7.1. By Key Regions
3.7.2. By Key Countries
3.8. Regional Parent Market Outlook
4. Global Market Analysis 2017-2021 and Forecast, 2022-2032
4.1. Historical Market Size Value (US$ Mn) Analysis, 2017-2021
4.2. Current and Future Market Size Value (US$ Mn) Projections, 2022-2032
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Therapy Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Mn) Analysis By Therapy Type, 2017-2021
5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Therapy Type, 2022-2032
5.3.1. Chemo-therapy
5.3.2. Stem Cell Therapy
5.3.3. Others
5.4. Y-o-Y Growth Trend Analysis By Therapy Type, 2017-2021
5.5. Absolute $ Opportunity Analysis By Therapy Type, 2022-2032 Deep-dive segmentation will be available in the sample on request
6. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Route of Administration
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Mn) Analysis By Route of Administration, 2017-2021
6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Route of Administration, 2022-2032
6.3.1. Orally
6.3.2. Intravenously
6.3.3. Intrathecally
6.3.4. Others
6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2017-2021
6.5. Absolute $ Opportunity Analysis By Route of Administration, 2022-2032 Deep-dive segmentation will be available in the sample on request
7. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Disease Type
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Mn) Analysis By Disease Type, 2017-2021
7.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Disease Type, 2022-2032
7.3.1. AML (Acute Myeloid Leukaemia)
7.3.2. ALL (Acute Lymphoblastic Leukaemia)
7.3.3. CLL (Chronic Lymphocytic Leukaemia)
7.4. Y-o-Y Growth Trend Analysis By Disease Type, 2017-2021
7.5. Absolute $ Opportunity Analysis By Disease Type, 2022-2032 Deep-dive segmentation will be available in the sample on request
8. Global Market Analysis 2017-2021 and Forecast 2022-2032, By End User
8.1. Introduction / Key Findings
8.2. Historical Market Size Value (US$ Mn) Analysis By End User, 2017-2021
8.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By End User, 2022-2032
8.3.1. Hospitals
8.3.2. Research Institutes
8.3.3. Others
8.4. Y-o-Y Growth Trend Analysis By End User, 2017-2021
8.5. Absolute $ Opportunity Analysis By End User, 2022-2032 Deep-dive segmentation will be available in the sample on request
9. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Region
9.1. Introduction
9.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2017-2021
9.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2022-2032
9.3.1. North America
9.3.2. Latin America
9.3.3. Europe
9.3.4. East Asia
9.3.5. South Asia & Pacific
9.3.6. MEA
9.4. Market Attractiveness Analysis By Region
10. North America Market Analysis 2017-2021 and Forecast 2022-2032, By Country
10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
10.2.1. By Country
10.2.1.1. U.S.
10.2.1.2. Canada
10.2.2. By Therapy Type
10.2.3. By Route of Administration
10.2.4. By Disease Type
10.2.5. By End User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Therapy Type
10.3.3. By Route of Administration
10.3.4. By Disease Type
10.3.5. By End User
10.4. Key Takeaways
11. Latin America Market Analysis 2017-2021 and Forecast 2022-2032, By Country
11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
11.2.1. By Country
11.2.1.1. Mexico
11.2.1.2. Brazil
11.2.1.3. Rest of Latin America
11.2.2. By Therapy Type
11.2.3. By Route of Administration
11.2.4. By Disease Type
11.2.5. By End User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Therapy Type
11.3.3. By Route of Administration
11.3.4. By Disease Type
11.3.5. By End User
11.4. Key Takeaways
12. Europe Market Analysis 2017-2021 and Forecast 2022-2032, By Country
12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
12.2.1. By Country
12.2.1.1. Germany
12.2.1.2. Italy
12.2.1.3. France
12.2.1.4. U.K.
12.2.1.5. Spain
12.2.1.6. BENELUX
12.2.1.7. Russia
12.2.1.8. Rest of Europe
12.2.2. By Therapy Type
12.2.3. By Route of Administration
12.2.4. By Disease Type
12.2.5. By End User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Therapy Type
12.3.3. By Route of Administration
12.3.4. By Disease Type
12.3.5. By End User
12.4. Key Takeaways
13. East Asia Market Analysis 2017-2021 and Forecast 2022-2032, By Country
13.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
13.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
13.2.1. By Country
13.2.1.1. China
13.2.1.2. Japan
13.2.1.3. South Korea
13.2.2. By Therapy Type
13.2.3. By Route of Administration
13.2.4. By Disease Type
13.2.5. By End User
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Therapy Type
13.3.3. By Route of Administration
13.3.4. By Disease Type
13.3.5. By End User
13.4. Key Takeaways
14. South Asia & Pacific Market Analysis 2017-2021 and Forecast 2022-2032, By Country
14.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
14.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
14.2.1. By Country
14.2.1.1. India
14.2.1.2. ASEAN
14.2.1.3. Australia and New Zealand
14.2.1.4. Rest of South Asia & Pacific
14.2.2. By Therapy Type
14.2.3. By Route of Administration
14.2.4. By Disease Type
14.2.5. By End User
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Therapy Type
14.3.3. By Route of Administration
14.3.4. By Disease Type
14.3.5. By End User
14.4. Key Takeaways
15. MEA Market Analysis 2017-2021 and Forecast 2022-2032, By Country
15.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
15.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
15.2.1. By Country
15.2.1.1. GCC Countries
15.2.1.2. Turkey
15.2.1.3. South Africa
15.2.1.4. Rest of MEA
15.2.2. By Therapy Type
15.2.3. By Route of Administration
15.2.4. By Disease Type
15.2.5. By End User
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Therapy Type
15.3.3. By Route of Administration
15.3.4. By Disease Type
15.3.5. By End User
15.4. Key Takeaways
16. Key Countries Market Analysis
16.1. U.S.
16.1.1. Pricing Analysis
16.1.2. Market Share Analysis, 2021
16.1.2.1. By Therapy Type
16.1.2.2. By Route of Administration
16.1.2.3. By Disease Type
16.1.2.4. By End User
16.2. Canada
16.2.1. Pricing Analysis
16.2.2. Market Share Analysis, 2021
16.2.2.1. By Therapy Type
16.2.2.2. By Route of Administration
16.2.2.3. By Disease Type
16.2.2.4. By End User
16.3. Mexico
16.3.1. Pricing Analysis
16.3.2. Market Share Analysis, 2021
16.3.2.1. By Therapy Type
16.3.2.2. By Route of Administration
16.3.2.3. By Disease Type
16.3.2.4. By End User
16.4. Brazil
16.4.1. Pricing Analysis
16.4.2. Market Share Analysis, 2021
16.4.2.1. By Therapy Type
16.4.2.2. By Route of Administration
16.4.2.3. By Disease Type
16.4.2.4. By End User
16.5. Germany
16.5.1. Pricing Analysis
16.5.2. Market Share Analysis, 2021
16.5.2.1. By Therapy Type
16.5.2.2. By Route of Administration
16.5.2.3. By Disease Type
16.5.2.4. By End User
16.6. Italy
16.6.1. Pricing Analysis
16.6.2. Market Share Analysis, 2021
16.6.2.1. By Therapy Type
16.6.2.2. By Route of Administration
16.6.2.3. By Disease Type
16.6.2.4. By End User
16.7. France
16.7.1. Pricing Analysis
16.7.2. Market Share Analysis, 2021
16.7.2.1. By Therapy Type
16.7.2.2. By Route of Administration
16.7.2.3. By Disease Type
16.7.2.4. By End User
16.8. U.K.
16.8.1. Pricing Analysis
16.8.2. Market Share Analysis, 2021
16.8.2.1. By Therapy Type
16.8.2.2. By Route of Administration
16.8.2.3. By Disease Type
16.8.2.4. By End User
16.9. Spain
16.9.1. Pricing Analysis
16.9.2. Market Share Analysis, 2021
16.9.2.1. By Therapy Type
16.9.2.2. By Route of Administration
16.9.2.3. By Disease Type
16.9.2.4. By End User
16.10. BENELUX
16.10.1. Pricing Analysis
16.10.2. Market Share Analysis, 2021
16.10.2.1. By Therapy Type
16.10.2.2. By Route of Administration
16.10.2.3. By Disease Type
16.10.2.4. By End User
16.11. Russia
16.11.1. Pricing Analysis
16.11.2. Market Share Analysis, 2021
16.11.2.1. By Therapy Type
16.11.2.2. By Route of Administration
16.11.2.3. By Disease Type
16.11.2.4. By End User
16.12. China
16.12.1. Pricing Analysis
16.12.2. Market Share Analysis, 2021
16.12.2.1. By Therapy Type
16.12.2.2. By Route of Administration
16.12.2.3. By Disease Type
16.12.2.4. By End User
16.13. Japan
16.13.1. Pricing Analysis
16.13.2. Market Share Analysis, 2021
16.13.2.1. By Therapy Type
16.13.2.2. By Route of Administration
16.13.2.3. By Disease Type
16.13.2.4. By End User
16.14. South Korea
16.14.1. Pricing Analysis
16.14.2. Market Share Analysis, 2021
16.14.2.1. By Therapy Type
16.14.2.2. By Route of Administration
16.14.2.3. By Disease Type
16.14.2.4. By End User
16.15. India
16.15.1. Pricing Analysis
16.15.2. Market Share Analysis, 2021
16.15.2.1. By Therapy Type
16.15.2.2. By Route of Administration
16.15.2.3. By Disease Type
16.15.2.4. By End User
16.16. ASEAN
16.16.1. Pricing Analysis
16.16.2. Market Share Analysis, 2021
16.16.2.1. By Therapy Type
16.16.2.2. By Route of Administration
16.16.2.3. By Disease Type
16.16.2.4. By End User
16.17. Australia and New Zealand
16.17.1. Pricing Analysis
16.17.2. Market Share Analysis, 2021
16.17.2.1. By Therapy Type
16.17.2.2. By Route of Administration
16.17.2.3. By Disease Type
16.17.2.4. By End User
16.18. GCC Countries
16.18.1. Pricing Analysis
16.18.2. Market Share Analysis, 2021
16.18.2.1. By Therapy Type
16.18.2.2. By Route of Administration
16.18.2.3. By Disease Type
16.18.2.4. By End User
16.19. Turkey
16.19.1. Pricing Analysis
16.19.2. Market Share Analysis, 2021
16.19.2.1. By Therapy Type
16.19.2.2. By Route of Administration
16.19.2.3. By Disease Type
16.19.2.4. By End User
16.20. South Africa
16.20.1. Pricing Analysis
16.20.2. Market Share Analysis, 2021
16.20.2.1. By Therapy Type
16.20.2.2. By Route of Administration
16.20.2.3. By Disease Type
16.20.2.4. By End User
17. Market Structure Analysis
17.1. Competition Dashboard
17.2. Competition Benchmarking
17.3. Market Share Analysis of Top Players
17.3.1. By Regional
17.3.2. By Therapy Type
17.3.3. By Route of Administration
17.3.4. By Disease Type
17.3.5. By End User
18. Competition Analysis
18.1. Competition Deep Dive
18.1.1. Novartis International AG
18.1.1.1. Overview
18.1.1.2. Product Portfolio
18.1.1.3. Profitability by Market Segments
18.1.1.4. Sales Footprint
18.1.1.5. Strategy Overview
18.1.1.5.1. Marketing Strategy
18.1.1.5.2. Product Strategy
18.1.1.5.3. Channel Strategy
18.1.2. GlaxoSmithKline Pharmaceuticals Limited
18.1.2.1. Overview
18.1.2.2. Product Portfolio
18.1.2.3. Profitability by Market Segments
18.1.2.4. Sales Footprint
18.1.2.5. Strategy Overview
18.1.2.5.1. Marketing Strategy
18.1.2.5.2. Product Strategy
18.1.2.5.3. Channel Strategy
18.1.3. Roche
18.1.3.1. Overview
18.1.3.2. Product Portfolio
18.1.3.3. Profitability by Market Segments
18.1.3.4. Sales Footprint
18.1.3.5. Strategy Overview
18.1.3.5.1. Marketing Strategy
18.1.3.5.2. Product Strategy
18.1.3.5.3. Channel Strategy
18.1.4. Bristol-Myers Squibb
18.1.4.1. Overview
18.1.4.2. Product Portfolio
18.1.4.3. Profitability by Market Segments
18.1.4.4. Sales Footprint
18.1.4.5. Strategy Overview
18.1.4.5.1. Marketing Strategy
18.1.4.5.2. Product Strategy
18.1.4.5.3. Channel Strategy
18.1.5. Genmab A/S
18.1.5.1. Overview
18.1.5.2. Product Portfolio
18.1.5.3. Profitability by Market Segments
18.1.5.4. Sales Footprint
18.1.5.5. Strategy Overview
18.1.5.5.1. Marketing Strategy
18.1.5.5.2. Product Strategy
18.1.5.5.3. Channel Strategy
18.1.6. Celgene Corporation
18.1.6.1. Overview
18.1.6.2. Product Portfolio
18.1.6.3. Profitability by Market Segments
18.1.6.4. Sales Footprint
18.1.6.5. Strategy Overview
18.1.6.5.1. Marketing Strategy
18.1.6.5.2. Product Strategy
18.1.6.5.3. Channel Strategy
18.1.7. Biogen
18.1.7.1. Overview
18.1.7.2. Product Portfolio
18.1.7.3. Profitability by Market Segments
18.1.7.4. Sales Footprint
18.1.7.5. Strategy Overview
18.1.7.5.1. Marketing Strategy
18.1.7.5.2. Product Strategy
18.1.7.5.3. Channel Strategy
18.1.8. Pfizer
18.1.8.1. Overview
18.1.8.2. Product Portfolio
18.1.8.3. Profitability by Market Segments
18.1.8.4. Sales Footprint
18.1.8.5. Strategy Overview
18.1.8.5.1. Marketing Strategy
18.1.8.5.2. Product Strategy
18.1.8.5.3. Channel Strategy
19. Assumptions & Acronyms Used
20. Research Methodology
Let us know your requirement to get
100% FREE customization
List of Tables
Table 1: Global Market Value (US$ Mn) Forecast by Region, 2017-2032
Table 2: Global Market Value (US$ Mn) Forecast by Therapy Type, 2017-2032
Table 3: Global Market Value (US$ Mn) Forecast by Route of Administration, 2017-2032
Table 4: Global Market Value (US$ Mn) Forecast by Disease Type, 2017-2032
Table 5: Global Market Value (US$ Mn) Forecast by End User, 2017-2032
Table 6: North America Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 7: North America Market Value (US$ Mn) Forecast by Therapy Type, 2017-2032
Table 8: North America Market Value (US$ Mn) Forecast by Route of Administration, 2017-2032
Table 9: North America Market Value (US$ Mn) Forecast by Disease Type, 2017-2032
Table 10: North America Market Value (US$ Mn) Forecast by End User, 2017-2032
Table 11: Latin America Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 12: Latin America Market Value (US$ Mn) Forecast by Therapy Type, 2017-2032
Table 13: Latin America Market Value (US$ Mn) Forecast by Route of Administration, 2017-2032
Table 14: Latin America Market Value (US$ Mn) Forecast by Disease Type, 2017-2032
Table 15: Latin America Market Value (US$ Mn) Forecast by End User, 2017-2032
Table 16: Europe Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 17: Europe Market Value (US$ Mn) Forecast by Therapy Type, 2017-2032
Table 18: Europe Market Value (US$ Mn) Forecast by Route of Administration, 2017-2032
Table 19: Europe Market Value (US$ Mn) Forecast by Disease Type, 2017-2032
Table 20: Europe Market Value (US$ Mn) Forecast by End User, 2017-2032
Table 21: East Asia Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 22: East Asia Market Value (US$ Mn) Forecast by Therapy Type, 2017-2032
Table 23: East Asia Market Value (US$ Mn) Forecast by Route of Administration, 2017-2032
Table 24: East Asia Market Value (US$ Mn) Forecast by Disease Type, 2017-2032
Table 25: East Asia Market Value (US$ Mn) Forecast by End User, 2017-2032
Table 26: South Asia & Pacific Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 27: South Asia & Pacific Market Value (US$ Mn) Forecast by Therapy Type, 2017-2032
Table 28: South Asia & Pacific Market Value (US$ Mn) Forecast by Route of Administration, 2017-2032
Table 29: South Asia & Pacific Market Value (US$ Mn) Forecast by Disease Type, 2017-2032
Table 30: South Asia & Pacific Market Value (US$ Mn) Forecast by End User, 2017-2032
Table 31: MEA Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 32: MEA Market Value (US$ Mn) Forecast by Therapy Type, 2017-2032
Table 33: MEA Market Value (US$ Mn) Forecast by Route of Administration, 2017-2032
Table 34: MEA Market Value (US$ Mn) Forecast by Disease Type, 2017-2032
Table 35: MEA Market Value (US$ Mn) Forecast by End User, 2017-2032
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 1: Global Market Value (US$ Mn) by Therapy Type, 2022-2032
Figure 2: Global Market Value (US$ Mn) by Route of Administration, 2022-2032
Figure 3: Global Market Value (US$ Mn) by Disease Type, 2022-2032
Figure 4: Global Market Value (US$ Mn) by End User, 2022-2032
Figure 5: Global Market Value (US$ Mn) by Region, 2022-2032
Figure 6: Global Market Value (US$ Mn) Analysis by Region, 2017-2032
Figure 7: Global Market Value Share (%) and BPS Analysis by Region, 2022-2032
Figure 8: Global Market Y-o-Y Growth (%) Projections by Region, 2022-2032
Figure 9: Global Market Value (US$ Mn) Analysis by Therapy Type, 2017-2032
Figure 10: Global Market Value Share (%) and BPS Analysis by Therapy Type, 2022-2032
Figure 11: Global Market Y-o-Y Growth (%) Projections by Therapy Type, 2022-2032
Figure 12: Global Market Value (US$ Mn) Analysis by Route of Administration, 2017-2032
Figure 13: Global Market Value Share (%) and BPS Analysis by Route of Administration, 2022-2032
Figure 14: Global Market Y-o-Y Growth (%) Projections by Route of Administration, 2022-2032
Figure 15: Global Market Value (US$ Mn) Analysis by Disease Type, 2017-2032
Figure 16: Global Market Value Share (%) and BPS Analysis by Disease Type, 2022-2032
Figure 17: Global Market Y-o-Y Growth (%) Projections by Disease Type, 2022-2032
Figure 18: Global Market Value (US$ Mn) Analysis by End User, 2017-2032
Figure 19: Global Market Value Share (%) and BPS Analysis by End User, 2022-2032
Figure 20: Global Market Y-o-Y Growth (%) Projections by End User, 2022-2032
Figure 21: Global Market Attractiveness by Therapy Type, 2022-2032
Figure 22: Global Market Attractiveness by Route of Administration, 2022-2032
Figure 23: Global Market Attractiveness by Disease Type, 2022-2032
Figure 24: Global Market Attractiveness by End User, 2022-2032
Figure 25: Global Market Attractiveness by Region, 2022-2032
Figure 26: North America Market Value (US$ Mn) by Therapy Type, 2022-2032
Figure 27: North America Market Value (US$ Mn) by Route of Administration, 2022-2032
Figure 28: North America Market Value (US$ Mn) by Disease Type, 2022-2032
Figure 29: North America Market Value (US$ Mn) by End User, 2022-2032
Figure 30: North America Market Value (US$ Mn) by Country, 2022-2032
Figure 31: North America Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 32: North America Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 33: North America Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 34: North America Market Value (US$ Mn) Analysis by Therapy Type, 2017-2032
Figure 35: North America Market Value Share (%) and BPS Analysis by Therapy Type, 2022-2032
Figure 36: North America Market Y-o-Y Growth (%) Projections by Therapy Type, 2022-2032
Figure 37: North America Market Value (US$ Mn) Analysis by Route of Administration, 2017-2032
Figure 38: North America Market Value Share (%) and BPS Analysis by Route of Administration, 2022-2032
Figure 39: North America Market Y-o-Y Growth (%) Projections by Route of Administration, 2022-2032
Figure 40: North America Market Value (US$ Mn) Analysis by Disease Type, 2017-2032
Figure 41: North America Market Value Share (%) and BPS Analysis by Disease Type, 2022-2032
Figure 42: North America Market Y-o-Y Growth (%) Projections by Disease Type, 2022-2032
Figure 43: North America Market Value (US$ Mn) Analysis by End User, 2017-2032
Figure 44: North America Market Value Share (%) and BPS Analysis by End User, 2022-2032
Figure 45: North America Market Y-o-Y Growth (%) Projections by End User, 2022-2032
Figure 46: North America Market Attractiveness by Therapy Type, 2022-2032
Figure 47: North America Market Attractiveness by Route of Administration, 2022-2032
Figure 48: North America Market Attractiveness by Disease Type, 2022-2032
Figure 49: North America Market Attractiveness by End User, 2022-2032
Figure 50: North America Market Attractiveness by Country, 2022-2032
Figure 51: Latin America Market Value (US$ Mn) by Therapy Type, 2022-2032
Figure 52: Latin America Market Value (US$ Mn) by Route of Administration, 2022-2032
Figure 53: Latin America Market Value (US$ Mn) by Disease Type, 2022-2032
Figure 54: Latin America Market Value (US$ Mn) by End User, 2022-2032
Figure 55: Latin America Market Value (US$ Mn) by Country, 2022-2032
Figure 56: Latin America Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 57: Latin America Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 58: Latin America Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 59: Latin America Market Value (US$ Mn) Analysis by Therapy Type, 2017-2032
Figure 60: Latin America Market Value Share (%) and BPS Analysis by Therapy Type, 2022-2032
Figure 61: Latin America Market Y-o-Y Growth (%) Projections by Therapy Type, 2022-2032
Figure 62: Latin America Market Value (US$ Mn) Analysis by Route of Administration, 2017-2032
Figure 63: Latin America Market Value Share (%) and BPS Analysis by Route of Administration, 2022-2032
Figure 64: Latin America Market Y-o-Y Growth (%) Projections by Route of Administration, 2022-2032
Figure 65: Latin America Market Value (US$ Mn) Analysis by Disease Type, 2017-2032
Figure 66: Latin America Market Value Share (%) and BPS Analysis by Disease Type, 2022-2032
Figure 67: Latin America Market Y-o-Y Growth (%) Projections by Disease Type, 2022-2032
Figure 68: Latin America Market Value (US$ Mn) Analysis by End User, 2017-2032
Figure 69: Latin America Market Value Share (%) and BPS Analysis by End User, 2022-2032
Figure 70: Latin America Market Y-o-Y Growth (%) Projections by End User, 2022-2032
Figure 71: Latin America Market Attractiveness by Therapy Type, 2022-2032
Figure 72: Latin America Market Attractiveness by Route of Administration, 2022-2032
Figure 73: Latin America Market Attractiveness by Disease Type, 2022-2032
Figure 74: Latin America Market Attractiveness by End User, 2022-2032
Figure 75: Latin America Market Attractiveness by Country, 2022-2032
Figure 76: Europe Market Value (US$ Mn) by Therapy Type, 2022-2032
Figure 77: Europe Market Value (US$ Mn) by Route of Administration, 2022-2032
Figure 78: Europe Market Value (US$ Mn) by Disease Type, 2022-2032
Figure 79: Europe Market Value (US$ Mn) by End User, 2022-2032
Figure 80: Europe Market Value (US$ Mn) by Country, 2022-2032
Figure 81: Europe Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 82: Europe Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 83: Europe Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 84: Europe Market Value (US$ Mn) Analysis by Therapy Type, 2017-2032
Figure 85: Europe Market Value Share (%) and BPS Analysis by Therapy Type, 2022-2032
Figure 86: Europe Market Y-o-Y Growth (%) Projections by Therapy Type, 2022-2032
Figure 87: Europe Market Value (US$ Mn) Analysis by Route of Administration, 2017-2032
Figure 88: Europe Market Value Share (%) and BPS Analysis by Route of Administration, 2022-2032
Figure 89: Europe Market Y-o-Y Growth (%) Projections by Route of Administration, 2022-2032
Figure 90: Europe Market Value (US$ Mn) Analysis by Disease Type, 2017-2032
Figure 91: Europe Market Value Share (%) and BPS Analysis by Disease Type, 2022-2032
Figure 92: Europe Market Y-o-Y Growth (%) Projections by Disease Type, 2022-2032
Figure 93: Europe Market Value (US$ Mn) Analysis by End User, 2017-2032
Figure 94: Europe Market Value Share (%) and BPS Analysis by End User, 2022-2032
Figure 95: Europe Market Y-o-Y Growth (%) Projections by End User, 2022-2032
Figure 96: Europe Market Attractiveness by Therapy Type, 2022-2032
Figure 97: Europe Market Attractiveness by Route of Administration, 2022-2032
Figure 98: Europe Market Attractiveness by Disease Type, 2022-2032
Figure 99: Europe Market Attractiveness by End User, 2022-2032
Figure 100: Europe Market Attractiveness by Country, 2022-2032
Figure 101: East Asia Market Value (US$ Mn) by Therapy Type, 2022-2032
Figure 102: East Asia Market Value (US$ Mn) by Route of Administration, 2022-2032
Figure 103: East Asia Market Value (US$ Mn) by Disease Type, 2022-2032
Figure 104: East Asia Market Value (US$ Mn) by End User, 2022-2032
Figure 105: East Asia Market Value (US$ Mn) by Country, 2022-2032
Figure 106: East Asia Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 107: East Asia Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 108: East Asia Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 109: East Asia Market Value (US$ Mn) Analysis by Therapy Type, 2017-2032
Figure 110: East Asia Market Value Share (%) and BPS Analysis by Therapy Type, 2022-2032
Figure 111: East Asia Market Y-o-Y Growth (%) Projections by Therapy Type, 2022-2032
Figure 112: East Asia Market Value (US$ Mn) Analysis by Route of Administration, 2017-2032
Figure 113: East Asia Market Value Share (%) and BPS Analysis by Route of Administration, 2022-2032
Figure 114: East Asia Market Y-o-Y Growth (%) Projections by Route of Administration, 2022-2032
Figure 115: East Asia Market Value (US$ Mn) Analysis by Disease Type, 2017-2032
Figure 116: East Asia Market Value Share (%) and BPS Analysis by Disease Type, 2022-2032
Figure 117: East Asia Market Y-o-Y Growth (%) Projections by Disease Type, 2022-2032
Figure 118: East Asia Market Value (US$ Mn) Analysis by End User, 2017-2032
Figure 119: East Asia Market Value Share (%) and BPS Analysis by End User, 2022-2032
Figure 120: East Asia Market Y-o-Y Growth (%) Projections by End User, 2022-2032
Figure 121: East Asia Market Attractiveness by Therapy Type, 2022-2032
Figure 122: East Asia Market Attractiveness by Route of Administration, 2022-2032
Figure 123: East Asia Market Attractiveness by Disease Type, 2022-2032
Figure 124: East Asia Market Attractiveness by End User, 2022-2032
Figure 125: East Asia Market Attractiveness by Country, 2022-2032
Figure 126: South Asia & Pacific Market Value (US$ Mn) by Therapy Type, 2022-2032
Figure 127: South Asia & Pacific Market Value (US$ Mn) by Route of Administration, 2022-2032
Figure 128: South Asia & Pacific Market Value (US$ Mn) by Disease Type, 2022-2032
Figure 129: South Asia & Pacific Market Value (US$ Mn) by End User, 2022-2032
Figure 130: South Asia & Pacific Market Value (US$ Mn) by Country, 2022-2032
Figure 131: South Asia & Pacific Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 132: South Asia & Pacific Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 133: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 134: South Asia & Pacific Market Value (US$ Mn) Analysis by Therapy Type, 2017-2032
Figure 135: South Asia & Pacific Market Value Share (%) and BPS Analysis by Therapy Type, 2022-2032
Figure 136: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Therapy Type, 2022-2032
Figure 137: South Asia & Pacific Market Value (US$ Mn) Analysis by Route of Administration, 2017-2032
Figure 138: South Asia & Pacific Market Value Share (%) and BPS Analysis by Route of Administration, 2022-2032
Figure 139: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Route of Administration, 2022-2032
Figure 140: South Asia & Pacific Market Value (US$ Mn) Analysis by Disease Type, 2017-2032
Figure 141: South Asia & Pacific Market Value Share (%) and BPS Analysis by Disease Type, 2022-2032
Figure 142: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Disease Type, 2022-2032
Figure 143: South Asia & Pacific Market Value (US$ Mn) Analysis by End User, 2017-2032
Figure 144: South Asia & Pacific Market Value Share (%) and BPS Analysis by End User, 2022-2032
Figure 145: South Asia & Pacific Market Y-o-Y Growth (%) Projections by End User, 2022-2032
Figure 146: South Asia & Pacific Market Attractiveness by Therapy Type, 2022-2032
Figure 147: South Asia & Pacific Market Attractiveness by Route of Administration, 2022-2032
Figure 148: South Asia & Pacific Market Attractiveness by Disease Type, 2022-2032
Figure 149: South Asia & Pacific Market Attractiveness by End User, 2022-2032
Figure 150: South Asia & Pacific Market Attractiveness by Country, 2022-2032
Figure 151: MEA Market Value (US$ Mn) by Therapy Type, 2022-2032
Figure 152: MEA Market Value (US$ Mn) by Route of Administration, 2022-2032
Figure 153: MEA Market Value (US$ Mn) by Disease Type, 2022-2032
Figure 154: MEA Market Value (US$ Mn) by End User, 2022-2032
Figure 155: MEA Market Value (US$ Mn) by Country, 2022-2032
Figure 156: MEA Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 157: MEA Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 158: MEA Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 159: MEA Market Value (US$ Mn) Analysis by Therapy Type, 2017-2032
Figure 160: MEA Market Value Share (%) and BPS Analysis by Therapy Type, 2022-2032
Figure 161: MEA Market Y-o-Y Growth (%) Projections by Therapy Type, 2022-2032
Figure 162: MEA Market Value (US$ Mn) Analysis by Route of Administration, 2017-2032
Figure 163: MEA Market Value Share (%) and BPS Analysis by Route of Administration, 2022-2032
Figure 164: MEA Market Y-o-Y Growth (%) Projections by Route of Administration, 2022-2032
Figure 165: MEA Market Value (US$ Mn) Analysis by Disease Type, 2017-2032
Figure 166: MEA Market Value Share (%) and BPS Analysis by Disease Type, 2022-2032
Figure 167: MEA Market Y-o-Y Growth (%) Projections by Disease Type, 2022-2032
Figure 168: MEA Market Value (US$ Mn) Analysis by End User, 2017-2032
Figure 169: MEA Market Value Share (%) and BPS Analysis by End User, 2022-2032
Figure 170: MEA Market Y-o-Y Growth (%) Projections by End User, 2022-2032
Figure 171: MEA Market Attractiveness by Therapy Type, 2022-2032
Figure 172: MEA Market Attractiveness by Route of Administration, 2022-2032
Figure 173: MEA Market Attractiveness by Disease Type, 2022-2032
Figure 174: MEA Market Attractiveness by End User, 2022-2032
Figure 175: MEA Market Attractiveness by Country, 2022-2032
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
